Erratum to: J Transl Med (2016) 14:236 DOI:10.1186/s12967-016-0995-5 {#Sec1}
====================================================================

Unfortunately, the original version of this article \[[@CR1]\] contained errors in the main text and in Tables 2 and 3. Tables 2 and 3 were included incorrectly. The correct Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} have been updated in the original article and are also included correctly in this erratum.Table 2Baseline characteristics of hemodialysis patients presented as groups according to MBL levelsPatientsP^\*^ \< 0.001RP^\#^All (n = 107)MBL low 319 \< ng/mL (n = 26)MBL high 319 ≥ ng/mL (n = 81)MBL range (ng/mL)821 \[319--1477\]98 \[33--146\]1290 \[671--1848\]*Demographics*Age, years62.5 ± 15.665.3 ± 12.161.56 ± 16.60.3−0.26*0.007*Male gender, n (%)71 (66)17 (65)54 (67)1.0Current diabetes, n (%)25 (24)9 (35)16 (20)0.2Hypertension, n (%)85 (84)22 (88)63 (83)0.8Cardiovascular history, n (%)26 (25)9 (35)15 (19)0.1BMI, kg/m^2^25.8 ± 4.427.0 ± 4.525.4 ± 4.40.1−0.030.8*Hemodialysis*Dialysis vintage, months25.5 \[8.5--52.3\]18.2 \[7.0--47.7\]32.8 \[9.1--53.3\]0.2−0.010.9*Primary renal disease, n (%)*Hypertension18 (17)4 (15)14 (17)1.0Diabetes14 (13)5 (19)9 (11)0.3ADPKD13 (12)3 (12)10 (12)1.0FSGS9 (8)4 (15)5 (6)0.2IgA nephropathy4 (4)0 (0)4 (5)0.6Chronic pyelonephritis3 (3)0 (0)3 (4)1.0Glomerulonephritis13 (12)2 (8)11 (14)0.7Other diagnoses16 (16)6 (23)10 (12)0.2Unknown17 (16)2 (8)15 (19)0.2Ultrafiltration volume, L2.55 ± 0.782.54 ± 0.822.56 ± 0.780.9−0.010.9Ultrafiltration rate, mL/kg/h8.56 ± 2.637.81 ± 2.398.80 ± 2.670.10.040.7*Systolic blood pressure*Predialysis, mmHg140.4 ± 25.1144.7 ± 26.4139.1 ± 24.70.3−0.170.08Postdialysis, mmHg131.8 ± 25.6136 ± 24.3130.4 ± 26.00.4−0.24*0.02Heart rate*Predialysis, bpm73 \[63--82\]71 \[62--82\]74 \[64--82\]0.30.110.3Postdialysis, bpm79 \[69--87\]75 \[65--86\]79 \[69--88\]0.40.130.2Kidney transplant, n (%)21 (20)4 (15)17 (21)[0.8]{.smallcaps}*Laboratory measurements*Hematocrit, %34.9 ± 3.834.5 ± 4.135.0 ± 3.70.60.040.7HbAlc, mmol/mol5.68 ± 0.985.80 ± 0.975.63 ± 0.980.5−0.150.2Albumin, g/L39 \[37--42\]39 \[37--42\]39 \[37--42\]0.90.010.9pH7.37 \[7.34--7.39\]7.37 \[7.32--7.39\]7.37 \[7.34--7.39\]0.70.050.6Calcium, mmol/L2.31 ± 0.162.31 ± 0.152.32 ± 0.160.90.030.7Phosphate, mmol/L1.67 ± 0.531.82 ± 0.471.65 ± 0.540.2−0.000.9hsCRP, mg/L6.7 \[2.8--10.9\]6.1 \[1.4--12.0\]6.7 \[3.0--10.9\]0.70.100.3*Medication*Aspirin, n (%)57 (54)11 (42)46 (64)0.3Calcium channel blockers, n (%)14 (13)3 (12)11 (14)1.0β-Blocker, n (%)61 (57)18 (69)43 (53)0.2ACE inhibitor, n (%)10 (10)3 (12)7 (9)0.7AT2-receptor antagonists, n (%)14 (13)2 (8)12 (15)0.5Statin, n (%)20 (19)5 (19)15 (19)1.0Diuretics, n (%)8 (8)3 (12)5 (6)0.4Italic values used to show which statistical testing was significant (below 0.05)Data are presented as mean ± SD or median \[IQR\]*BMI* body mass index, *ADPKD* autosomal dominant polycystic kidney disease, *FSGS* focal segmental glomerulosclerosis, *HDA1c* hemoglobin A1c, *pH* potential hydrogen, *hsCRP* high sensitive C-relative protein, *ACE* inhibitor angiotensin-converting-enzyme inhibitor, *AT2 receptor antagonists* Angiotensin II receptor antagonistsP\* indicates P value for the difference in baseline characteristics between the MBL groups, tested by Student's t test or Mann--Whitney U test for continuous variables and with χ^2^ test for categorical variables; *R* indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; P^\#^ indicates the corresponding P valueTable 3Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patientsLow MBLLog MBL continuousHR95 % CI*P*HR (per SD)95 % CI*P*Cardiovascular events Model 12.641.36--5.13*0.004*0.640.46--0.90*0.01* Model 22.751.39--5.44*0.004*0.610.43--0.88*0.008* Model 32.941.45--5.94*0.003*0.610.42--0.89*0.01* Model 43.551.70--7.40*0.001*0.580.40--0.84*0.004* Model 53.981.88--8.42\<*0.001*0.560.38--0.81*0.002*Cardiac events Model 12.601.10--6.18*0.03*0.710.46--1.100.1 Model 22.491.04--5.96*0.04*0.730.46--1.160.2 Model 32.651.08--6.55*0.03*0.740.47--1.180.2 Model 43.821.48--9.87*0.006*0.620.38--1.010.06 Model 53.961.49--10.54*0.006*0.590.35--0.98*0.04*Model 1: crudeModel 2: adjusted for age and genderModel 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintageModel 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressureModel 5: adjusted for model 4 plus hsCRPData are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL increaseItalic values used to show which statistical testing was significant (below 0.05)*MBL* mannose-binding lectin, *HD* hemodialysis, *hsCRP* high sensitive C-reactive protein

Additionally, the following section has been corrected:

However, after adjustment MBL for these confounders levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.

Should read:

However, after adjustment for these confounders, MBL levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.
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